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Preamble
Numerous articles have been published in 2014 regarding valvular
heart diseases. Many papers focused on percutaneous interventions:
transcatheteraortic valve implantationandpercutaneousmitral valve
repair. This article presents the most relevant articles published in
2014 in this important clinical setting.
Epidemiology
Valvular heart disease remains frequent but is subject to temporal
and spatial epidemiological heterogeneity and this has important con-
sequences on patient management. The predominance of degenera-
tive aetiologies in industrialized countries accounts for the high
burden of valve disease in elderly patients with comorbidities. Un-
fortunately, it is not possible today to accurately estimate the preva-
lence of chronic secondary mitral regurgitation (MR) from available
population-based studies as they do not comprise an analysis of ana-
tomical features andmechanisms of MR. This should be dealt with by
running prospective registries with homogenous echocardiographic
assessment.1
Guidelines
The recently issued ACC/AHA guidelines in 20142 are largely con-
cordant, with respect to most recommendations, with the 2012
ESC/EACTS guidelines.3 The rare discrepancies and the number of
level C recommendations highlight the need for further randomized
studies and large registries. Both documents stress the importance
of risk assessment and shared decision-making emphasizing the
need for an individualized approach.
Aortic stenosis
The Edinburgh group showed the relationship between high tropo-
nin concentration and left ventricular (LV) hypertrophy. Patients
with high troponin levels had more advanced hypertrophy and
myocardial fibrosis. There was also a relationship between the level
of troponin I and outcome. These findings suggest the potential
interest of this biomarker in the early stages when timing of surgery
is discussed.4
The entity of patients with ‘paradoxical low-flow low-gradient
aortic stenosis and preserved ejection fraction’ continues to solicit
interest. Pibarot and coworkers performed a careful studymeasuring
the weight of operatively excised valves and showed that, when cor-
rected for gender and anatomic type, there is no difference in the
weight of aortic valves from patients with normal flow and high
gradient and those with paradoxical low flow, low gradient.5 Similar-
ly, there was no significant difference in the percentage of severe
aortic stenosis between these two groups. Thus, these data
provide further information for the characterization of this entity
and support the use of multidetector computed tomography in the
quantification of calcification to assess the severity of aortic stenosis
in these patients.
A paper of major interest for practising cardiologists evaluated the
risk of non-cardiac surgery in a large group of patients who under-
went either intermediate- or high-risk surgery with contemporary
practices.6 There was no difference in survival but more major
cardiac events were observed in patients with aortic stenosis espe-
cially due to heart failure. Most complications occurred when non-
cardiac surgery was performed in an emergency. The presence of
symptoms is very important in preoperative risk stratification since
asymptomatic patients did very well.
Transcatheter aortic valve implantation (TAVI) is nowwidely used
worldwidewhich increases the numberof patientswith severe aortic
stenosis who receive intervention using either surgery or TAVI.
However, a recent prospective registry conducted in several pro-
vinces in Spain showed that among octogenarians with severe symp-
tomatic aortic stenosis too many patients (46%) are still managed
conservativelywhich is associatedwith poor prognosis. This stresses
the need for continuous education according to the guidelines.7
Transcatheter aortic valve implantation
Patient selection is one of the crucial steps of TAVI. Surgical risk
scores, such as the STS PROM and EuroScore, have been shown to
be sub-optimal for estimating the risk of surgery. However, decision-
making also needs to be supported by evaluation of the risk of TAVI
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by ‘TAVI risk scores’. The first attempt to develop a TAVI risk score
was recently published by Iung et al. from the FRANCE 2 registry
with the aim of predicting 30-day mortality. The authors developed
and validated a multifactorial risk model including pre-procedural
factors related to impaired cardiovascular status, non-cardiac co-
morbidities, and one factor related to procedural strategy. Calibra-
tion of the score was good; however, the discrimination was only
moderate. The reasons for this moderate prediction performance
were probably multiple: the number of patients may be insufficient
and the very high-risk patients included in this trial may have too
many comorbidities to be captured in any score. In particular,
there was no precise assessment of frailty8; peri-procedural compli-
cations were not taken into account even though they still occur fre-
quently.9 The PARTNER investigators developed a risk score
predicting poor outcome at 6 months integrating quality of life with
mortality. Here, again there was only moderate discrimination and
a good calibration.10
Despite being imperfect, these TAVI risk scores may help to guide
treatment choice andoffer patients realistic expectationsofoutcome
based on their presenting characteristics.
An interesting paper looking at patients judged to be surgically
inoperable showed that patients who were inoperable for technical
reasons (porcelain aorta, previous bypass, and hostile chest) had
better survival and quality-of-life improvement after TAVI than
those who were inoperable due to clinical co-morbidities.11 In this
regard, the decision to perform TAVI may be more ‘futile than
utile’ in patients who were shown to have very poor outcome
after TAVI such as those with advanced chronic kidney disease
treated by dialysis who also had atrial fibrillation12 or patients
with chronic lung disease who are poorly mobile and/or oxygen
dependent.13
For the first time, a randomized trial comparing TAVI, using a self-
expanding transcatheter aortic valve bioprosthesis, with surgical
valve replacement in 795 patients at high risk, showed significant
survival benefit in favour of TAVI (mortality at 1 year 14.2 vs.
19.1%; P ¼ 0.004) (Figure 1). It should be noted that a similar com-
parison in PARTNER A only showed non-inferiority for TAVI.
However, patients included in PARTNER were at higher risk and
PARTNER was conducted in 2007 when the TAVI technique, in par-
ticular valve sizing, was less mature.14
Several important registries [GARY (n ¼ 13 860), ADVANCE
(n ¼ 1015), extreme risk study (n ¼ 506), TVT (n ¼ 6190)]15–18
consistently showed that survival after TAVI improves over time.
However, there remain concerns related to complications such as
moderate-to-severe paravalvular leaks which carry a poor prognosis
while the prognostic impact of mild paravalvular leak is still debated.
This complicationwill decrease in the futuredue tobetter sizing using
three-dimensional imaging and new technologies.19 The recently
published REPRISE 2 trial is promising in this respect showing an inci-
dence of moderate-to-severe aortic regurgitation of 1%.20 Stroke
frequency after TAVI has been declining and is probably not higher
than that of surgery.14 This complication may decrease thanks to
the use of protection devices.21 Strokes remain an issue. Over
time, it seems that stroke frequency after TAVI has been declining
due to improvement in patient selection, use of lower profile cathe-
ters,more careful anti-coagulation and better preventionof atrial fib-
rillation. A recent randomized comparison, including a neurologic
assessment, showed that the incidence of major stroke after TAVI
is not superior to that of surgery.22 In addition, protection devices
have shown promising signs of efficacy in preliminary evaluation.
There is still an ongoing debate on the long-term consequences of
pacemaker implantation and the best strategy to use in patients
with concomitant coronary artery disease,23 and the consequences
of new-onset persistent left bundle branch block.24
The first comparison between balloon-expandable vs. self-
expandable valves was presented by the CHOICE trial. The
Figure 1 Kaplan–Meier cumulative frequency of death from any cause.
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primary endpoint of this trial ‘device success’ was more frequent in
the balloon-expandable valve (95.9 vs. 77.5%, P, 0.001) due to a
significantly lower frequency of residual rather than mild aortic
regurgitation (4.1 vs. 18.3%) and less frequent need for implantation
of .1 valve. In addition, the need for permanent pacemaker was
three times higher for patients treated with a self-expanding valve.
This trial is important but a longer follow-up and a larger number
of patients are needed to determine whether differences in device
success will translate into clinically relevant overall benefit.22 This
trial opens the debate as to whether head-to-head comparisons
between the two devices currently used and newcomers will be
needed in the future.
The recommendations in the field of TAVI are similar in the ACC/
AHA and the ESC guidelines limiting the use of TAVI to medico-
surgical centres where a Heart Team selects high-risk or inoperable
patients.
As a useful summary about the technique, a comprehensive review
by Bax et al. addresses a number of issues which remain open in TAVI
as regards patient selection, treatment strategy, procedural issues,
and outcome after the procedure.25,26
Aortic regurgitation
A multicentre retrospective study looking at the progression of
aortic dilatation in adults with bicuspid valve showed that tubular
ascending aorta dilatation is the most common pattern and also
has the fastest growing rate. Aortic dilatation progresses equally
quickly in bicuspid valve at the level of the tubular segment and in
Marfan patients at the level of the Valsalva sinuses but does not
progress at all in a significant proportion of patients with bicuspid
valve. In addition, baseline aortic diameter does not predict progres-
sion rate. Therefore, systematic follow-up is warranted in patients
with bicuspid valve.27 Four-dimensional cardiovascularmagnetic res-
onance can assess flow and wall shear stress patterns in ascending
aorta. Higher shear forces in patients with bicuspid aortic valve
may influence the development of aortic dilatation and the follow-up
of patients at risk for aortic dilatation.28
The results of TAVI in pure or predominant aortic regurgitation
available so far are very limited and suggest that the procedure
is feasible. However, the incidence of moderate-to-severe aortic
regurgitation seems to be high and a second valve is frequently
needed.29 Indications are likely to be limited in industrialized coun-
tries where aortic regurgitation is mostly of degenerative origin
and where dilatation/aneurysm of the ascending aorta requires
treatment.
Mitral regurgitation
Patientswith severe symptomaticMRand heart failure remain largely
untreated as suggested years ago by the EuroHeart Survey, and con-
firmedby recentobservations.30Accuratequantitativeassessmentof
the severity of MR is essential. In primary MR, regurgitant fraction
using LV volumes obtained by 3D echography is highly feasible and
reliable for identification of severe MR.31
The recent AHA/ACC guidelines revised the definition of severe
secondary MR from an effective regurgitant orifice area (EROA) of
0.4–0.2 cm2 and from a regurgitant volume of 60–30 mL2. This
change has generated controversy. The measurement of EROA is
imprecise and the determination of MR severity should consider
the relationship between EROA and LV end-diastolic volume at dif-
ferent haemodynamic changes. Smaller LV volumes are associated
with lower EROA thresholds and larger LV volumes with higher
EROA thresholds. Careful integration of all echocardiographic data
must be used to define severe secondary MR.
Surgery
Practice guidelines recommend surgery in patients with severe
ischaemic MR, but do not specify whether to repair or replace the
mitral valve, becauseof lackof evidence for indicatingwhich interven-
tion is superior. Many surgeons prefer to repair with an undersized
complete ring. A randomized trial including 251 patients showed
no significant difference in LV reverse remodelling or survival at 12
months between patients who underwent mitral valve repair and
those who underwent valve replacement whereas replacement
provided a more durable correction of MR.32
Mitral valve annuloplasty may cause functional mitral stenosis,
especially during exercise and have been shown to be associated
with lack of mitral valve opening reserve, elevated postoperative ex-
ercise systolic pulmonary arterial pressure compared with mitral
valve replacement.33
ESC/EACTS guidelines indicate that surgery should be considered
in patients with moderate MRwho are submitted to coronary artery
bypass grafting (CABG) (class IIa, level of evidence C).3 A recent
study randomly assigned 301 patients with moderated ischaemic
MR toCABGaloneorCABGplusmitral valve repair. Repairwas per-
formed using complete, downsized by two sizes, annuloplasty rings.
At 1 year, the combined procedure did not result in a higher
degree of LV reverse remodelling but was associated with a longer
bypass time, a longer hospital stay after surgery andmore neurologic
events. No significant between-groups differences were foreseen in
major adverse cardiac or cerebrovascular events, deaths, readmis-
sions, functional statusorqualityof life.A longer follow-up is required
to assess whether the lower prevalence of MR after combined
surgery translates into a better clinical benefit.34
Percutaneous mitral valve repair
The current clinical experience of transcatheter mitral valve inter-
vention is almost exclusively limited to the MitraClip system with
which over 15 000 patients have been treated. The criteria for ana-
tomic selection of patients has been addressed in a very comprehen-
sive review by Wunderlich and Siegel (Figure 2).35
The follow-up results of the randomized clinical trial EVEREST II
were reported up to 4 years36 showing stable improvement in
valve function and sustained clinical benefit after successful proced-
ure from 30 days up to 4 years.
A large number of patients have been included in registries where
the majority of patients did not fulfil the inclusion criteria for
EVEREST as theywere high-risk with secondaryMR. These registries
confirmed the safety of the procedure in expert hands and improve-
ment of symptoms mid-term while the majority of patients still have
mild-to-moderate residual MR.37 Most patients in these registries
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have secondary MR. In this group, the outcomes are poor in patients
treated at a tooadvanced stageof thedisease reflectedbya ‘too large’
left ventricle or very high levels of BNP.38
In patients with primaryMR, some promising data39,40 suggest that
when performed by experienced teams, this treatment may provide
satisfactory results in terms of safety and clinical outcome in high-risk
patients. The mid-term results are closely related to MR severity at
discharge. The mid-term outcome seems to be more favourable in
patients successfully treated with primary MR than those with sec-
ondary MR.
Figure 2 Ideal (upper panel) and unsuitable (lower panel) morphologies for aMitraclip implantation. Ideal morphologies for a MitraClip implant-
ation. The pathology should be located in the middle segments (A and D) with no calcification in the grasping area as shown in an intercommissural
view in (D). (B) Some remaining degree of coaptation (red arrows, ideally at least 2 mm), the yellow line represents the coaptation depth (ideally
,11 mm). The yellow arrow in (C) follows a posterior leaflet with enough tissue for grasping (ideally ≥10 mm) and the red arrow illustrates the
measurement of a flail gap (ideally ,10 mm). In (E), the flail width is marked with a red arrow (ideally ,15 mm) (P2 prolapse in a non-surgical
view). Unsuitable morphologies for a MitraClip implantation. In (A), a gap between the anterior and posterior leaflet is documented in a 3D recon-
struction of the mitral valve (MVQ, Q-lab software, Philips). In (B), the white arrows point towards a surgically implanted mitral ring, the red arrow
marks a gap as a result of amissing posterior leaflet (no tissue to grasp), the anterior leaflet is retracted in addition. An anterior cleft is illustrated in an
en face view from the LA (C) and an en face view from the LV (D). In (E), an example of a severemitral stenosis is shown in a 3D LA aspect. Ao, aorta;
AL, antero-lateral; PM, postero-medial; LA, left atrium. With permission fromWunderlich and Siegel.35
L.A. Pierard and A. VahanianPage 4 of 7





Patients submitted to MitraClip procedure who have moderate–
severe tricuspid regurgitation (TR) show impaired safety at 30 days.
Moderate–severe TR independently predicted death and rehospita-
lization for heart failure at 12 months.41
The 2014 ACC/AHA recommendations on valvular heart disease
state that this technique may be considered in severely symptomatic
patients with chronic severe primary MR who have reasonable life
expectancy but a prohibitive surgical risk due to severe comorbidity.2
This recommendation is consistent with the ESC/EACTS guidelines
as regards the need for comprehensive assessment by a heart team
and limitation of the use of the technique to highly selected patients
at high risk. However, they differ concerning the recommendations
on the type of MR. This clearly mandates more clinical research
trials such as COAPT, RESHAPE, and Mitra Fr in patients with sec-
ondary MR.
More anecdotal reports have been published on the use of
transcatheter intervention after surgical failure, transcatheter
‘valve-in-a-valve’,42 valve in a ring implantation,43 or the first-in-man
transcatheter mitral valve replacement in patients with calcified
mitral annulus.44 Finally, a review of the pre-clinical and early clinical
evaluation of percutaneous transcatheter mitral valve replacement
was provided by DeBaker.45
Mitral stenosis
Cardiac magnetic resonance has been shown to reliably measure
planimetric mitral valve area.46 A new scoring system including new
quantitative echocardiographic parameters has been shown to
improve the prediction of outcomes following percutaneous
balloon commissurotomy.47 This study confirmed however that
anatomic parameters are only part of the prediction of the long-term
results of the procedure which are also independently influenced
by age, degree of MR, and post-procedural haemodynamic data.
Further analysis of the very long-term results after previous mitral
commissurotomy has shown that almost half of patients remain free
from surgery up to 20 years after a successful intervention. Repeat
percutaneous intervention can be performed in 1 of 4 cases allowing
postponement of surgery.48 In patients who present restenosis after
surgical commissurotomy, percutaneous commissurotomy can be
performed; when the results are good, 1 in 3 patients remain free
from surgery and 1 in 5 has good functional results up to 20
years.49 The technique can also provide satisfactory long-term func-
tional improvement in patients with mild calcification50 or when
calcification is localized to one commissure in patients with other-
wise favourable clinical characteristics.51
Endocarditis
Antibiotic prophylaxis given before invasive dental procedures for
infective endocarditis prevention is limited to patients at high risk
according to the ESC guidelines.52 In UK, the National Institute for
Health and Clinical Excellence (NICE) recommended in 2008
complete cessation of antibiotic prophylaxis.53 Prevention of infect-
ive endocarditis fell substantially after the introduction of the NICE
guidance, but the number of cases of infective endocarditis in
England increased significantly about the projected historical
trend.54 However, these data do not establish a causal association
and large-scale prospective, randomized controlled studies are
warranted.55
Conclusion
Many studies published in 2014 have important clinical implications.
Some contrast with the most recent ESC/EACTS and AHA/ACC
guidelines. The ESC/EACTS guidelines published in 2012 will prob-
ably require an update in the next future.
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